Frontage Laboratories acquires Concord Biosciences: ‘Committed to build a global CRO’

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/pichet_w)
(Image: Getty/pichet_w)
Frontage Laboratories has acquired Concord Biosciences, taking a “significant step” towards the company’s goal of building a global organization, says CEO.

Frontage Laboratories Inc. is a full-service early-stage contract research organization (CRO) with locations in the US and China. Last week the Exton, PA-headquartered company announced its acquisition of Concord Biosciences.

Previously under the name Ricerca Biosciences LLC, Concord Biosciences is a preclinical CRO located on a 20-acre campus near Cleveland, OH. The company conducts drug safety, metabolism, bioanalytical, residue and environmental fate studies.

Dr. Song Li, founder and CEO of Frontage Laboratories, said the acquisition is a “significant step”​ toward reaching the company’s goal of building a global CRO with integrated services.

“The addition of Concord Bio to the Frontage family will enable us to provide pharmaceutical product development services from lead selection to IND-enabling studies to commercialization,” ​he said in a press release. “Additionally, the agrochemical expertise of Concord Bio will position Frontage as a major CRO in the agricultural products industry."

Frontage Laboratories has not responded to a request for comment.

Related news

Show more

Related products

show more

Next generation ePRO from SQN Health

Next generation ePRO from SQN Health

Syne Qua Non Clinical | 16-May-2018 | Business Advice

In an era of rapid technology growth, healthcare requires low cost solutions for real-time data collection. We have come a long way from paper to EDC and...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars